A Pre-Generation of Emergency Reference Plan Model of Public Health Emergencies with Case-Based Reasoning.

Background and Purpose: In the early 21st century, the coronavirus alone has ravaged the world three times. Public health emergencies have caused a tremendous negative impact on public health, daily life, and global economic development, for having the characteristics of complexity and great harm. To tackle these problems, a pre-generation of emergency reference plan model of public health emergencies is proposed to better deal with the outbreak and spread of public health events. Methods: The method is divided into three stages. First, the modified SEIR model is used to predict the attribute values of the target case. Then, the similar case sets are extracted and filtered by calculating the similarity through the cross-efficiency evaluation method with the parallel system. Finally, the multi-stage emergency effect evaluation model is conducted so that the emergency plan with the best response effect at this stage can be made for reference. Results: We collected 25 typical events of COVID-19 that occurred in 11 cities in China as historical case bases and target cases, respectively. The result of the experiment verified the feasibility and effectiveness of the proposed method. Conclusion: This paper presents a new perspective on making a public health emergency plan, which could improve the decision-making accuracy and efficiency, maximize the emergency effect and save precious time for emergency response. This model can provide rapid decision supports for decision-making for public services such as government departments, centers for disease control, medical emergency centers and transport authorities, etc.

Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.

Inducing durable and effective immunity against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) via vaccination is essential to combat the current pandemic of coronavirus disease 2019 (COVID-19). It has been noticed that the strength of anti-COVID-19 vaccination-induced immunity fades over time, which calls for an additional vaccination regime, as known as booster immunization, to restore immunity among previously vaccinated populations. Here we report a pilot open-label trial of a third dose of BBIBP-CorV, an inactivated SARS-CoV-2 vaccine (Vero cell), on 136 participants aged between 18 to 63 years. Safety and immunogenicity in terms of neutralizing antibody titers and cytokine/chemokine responses were analyzed as the main endpoint until day 28. While systemic reactogenicity was either absent or mild, SARS-CoV-2-specific neutralizing antibody titers rapidly arose in all participants within 4 weeks, surpassing the peak antibody titers elicited by the initial two-dose immunization regime. Broad increases of cellular immunity-associated cytokines and chemokines were also detected in the majority of participants after the third vaccination. Furthermore, in an exploratory study, a newly developed recombinant protein vaccine, NVSI-06-08 (CHO Cells), was found to be safe and even more effective than BBIBP-CorV in eliciting humoral immune responses in BBIBP-CorV-primed individuals. Together, these results indicate that a third immunization schedule with either homologous or heterologous vaccine showed favorable safety profiles and restored potent SARS-CoV-2-specific immunity, providing support for further trials of booster vaccination in larger populations.